Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016382 (flushing)
 6,387 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Synthetic thyrotrophin-releasing hormone (TRH) given intravenously in doses of 50 mug or more causes a significant rise in serum thyroid-stimulating hormone (TSH) levels but has no effect on serum growth hormone, plasma luteinizing hormone, or plasma 11-hydroxycorticosteroids under carefully controlled basal conditions.The peak TSH response to intravenous TRH occurs at 20 minutes. The mild and transient side effects, which occur only after intravenous TRH, include nausea, a flushing sensation, a desire to micturate, a peculiar taste, and tightness in the chest. There is considerable variability in response to a given dose of TRH in the same subject on different occasions and in different subjects. Oral administration of TRH in doses of 1 mg and above causes a rise in serum TSH, maximal at two hours, a consistent response being obtained at doses of 20 mg and above. A rise in serum protein-bound iodine (P.B.I.) follows that of TSH, a consistent response being observed at 40-mg doses of TRH orally. Measurements of serum TSH after intravenous administration of TRH or of serum TSH or serum P.B.I. after oral TRH should prove useful tests of pituitary TSH reserve.
 ...
PMID:Further observations on the effect of synthetic thyrotropin-releasing hormone in man. 410 6

Clinical experience with a 4.3% solution of plasma protein treated to render it free of the agent of serum hepatitis is satisfactory. Sixty-seven transfusions of 400 ml. of the commercial preparation were given to 33 patients (25 with acute blood loss, 4 with severe burns, and 4 with hypoproteinaemia secondary to hepatic or renal disease).The solution was clinically as effective as reconstituted dried plasma in expanding plasma volume and in replacing serum protein lost in burns. Adverse effects were mild pyrexial reactions in one case and facial flushing in another. No cases of serum hepatitis occurred.The solution is available for immediate use, it can be kept at room temperature, and, as it does not cause rouleaux formation, it can be given before blood is taken for grouping and cross-matching.
 ...
PMID:Experience with a hepatitis-free plasma protein solution. 566 90

The pharmacokinetic properties of intravenously administered vancomycin were studied in four healthy volunteers. Reversible adverse effects (flushing, tachycardia, pruritus) occurred in two subjects who received high-dose rapid intravenous infusions. Distribution of vancomycin proceeded as a biphasic process in all four subjects. The initial distribution half-life (t1/2 alpha) was less than 8 minutes in all cases, with intermediate half-lives (t1/2 pi) varying from 0.43 to 1.48 hour and elimination half-lives (t1/2 beta) varying from 4.7 to 11.2 hours. Vancomycin clearance was less than creatinine clearance, probably because of serum protein binding, which was determined to be 55 per cent.
 ...
PMID:Single-dose kinetics of intravenous vancomycin. 738 Oct 31